RenovoRx, Inc. (RNXT)
- Previous Close
1.0300 - Open
1.0600 - Bid 0.9717 x 100
- Ask 1.0800 x 100
- Day's Range
1.0300 - 1.0600 - 52 Week Range
0.7500 - 1.6900 - Volume
24,212 - Avg. Volume
117,050 - Market Cap (intraday)
37.648M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4000 - Earnings Date May 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.38
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
renovorx.comRecent News: RNXT
View MorePerformance Overview: RNXT
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RNXT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RNXT
View MoreValuation Measures
Market Cap
37.65M
Enterprise Value
30.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
533.47
Price/Book (mrq)
8.41
Enterprise Value/Revenue
715.63
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-143.08%
Return on Equity (ttm)
-1,192.69%
Revenue (ttm)
43k
Net Income Avi to Common (ttm)
-8.81M
Diluted EPS (ttm)
-0.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
7.15M
Total Debt/Equity (mrq)
6.21%
Levered Free Cash Flow (ttm)
-5.41M